Storia in 4 fonti

ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer

To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts. | To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

fiercebiotech.comStai leggendo8 h fa

ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer

originale

ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer

Confronto fonti

ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer

Timeline cronologica

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker

ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the…

Roche details narrow failure of breast cancer pill trial

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With…

Roche details narrow failure of breast cancer pill trial

ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer